E-Newsletter - December 2017

meet alliance executive officers

Meet the Alliance Executive Officers! These physicians oversee the development of Alliance clinical trials in their specific area of responsibility and report on progress to the Alliance Central Protocol Operations Program Director and Principal Investigator. The executive officers also serve as key advisors to study chairs, and act as liaisons to the National Cancer Institute.

Selina Chow, MD
Executive Officer for Cancer Control Program

Dr. Chow is a Clinical Associate in the Section of Geriatrics and Palliative Medicine in the Department of Medicine at the University of Chicago Medicine.  Board certified in geriatrics and medical oncology, her research is centered on developing models of clinical care for older cancer patients and quality improvement with the delivery of supportive oncology care. Her clinical interests include comprehensive geriatric assessment for older adults and treatment of older frail adults with solid tumor malignancies.

Shira N. Dinner, MD
Executive Officer for Leukemia, Lymphoma, Myeloma and Transplant Research

Dr. Dinner is an Assistant Professor of Medicine in the Division of Hematology and Oncology at Northwestern University Feinberg School of Medicine. Her research interests include novel molecularly targeted therapies for leukemia, in particular acute lymphoblastic leukemia (ALL). She also serves on the National Comprehensive Cancer Network (NCCN) Myeloid Growth Factor Committee and the Adolescent and Young Adult Committee, which is highly relevant to a large age group represented in adult ALL.

Priya Kumthekar, MD
Executive Officer for Neuro-Oncology and Gastrointestinal (GI) Research

Dr. Kumthekar is an Assistant Professor of Neurology in the Division of Neuro-Oncology and of Medicine in the Division of Hematology and Oncology at Northwestern University Feinberg School of Medicine. She is the lead investigator of several clinical trials, including her own investigator initiated clinical trials, along with Alliance trials and industry trials. Her interests include treating primary brain tumors such as gliomas and meningiomas, and in metastatic disease to the brain from systemic cancers such as melanoma, lung and breast cancer. She is also interested in quality of life care for her patients and supportive oncology.

Linda Skoog-Sluman, MD
Executive Officer for Breast, Genitourinary (GU), Experimental Therapeutics & Rare Tumor and Respiratory Research

Dr. Skoog-Sluman is a medical oncologist, and has previously worked as an Attending Physician in the Department of Hematology/Oncology at the University of Chicago. Her research interests include breast cancer in high-risk women and gynecological (ovarian, cervical) oncology. She has published in several peer reviewed periodicals including the Annals of Oncology. She has also served for 10 years as the Chief Medical Officer and founder of a disease prevention and health promotion company. In that capacity, she conceptualized, built and executed programs designed to improve employee health and lower health care costs.



For other articles in the December issue of the Alliance E-News newsletter, see below.